Improving immune response against brain tumors
Regulation of Tumor Immunogenicity in Glioblastoma
This study is looking at how to boost the immune system's fight against glioblastoma, a tough brain tumor, by tweaking certain proteins in the tumor cells so that T cells can better spot and attack them, which could lead to better treatments for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11036402 on NIH RePORTER |
What this research studies
This research investigates ways to enhance the immune system's ability to fight glioblastoma, a highly aggressive brain tumor. The approach focuses on understanding how certain proteins in tumor cells can be modified to increase their visibility to T cells, which are crucial for an effective immune response. By inhibiting a specific protein called PP2A, the researchers aim to improve the expression of molecules that help T cells recognize and attack the tumor. This could potentially lead to more effective immunotherapy treatments for patients with glioblastoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with glioblastoma who are 21 years or older.
Not a fit: Patients with other types of brain tumors or those who are not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new immunotherapy strategies that significantly improve survival rates for patients with glioblastoma.
How similar studies have performed: Previous research has shown that enhancing immune responses in glioblastoma through similar mechanisms has potential, but this specific approach is still being explored.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Ho, Sze Chun Winson — University of California, San Francisco
- Study coordinator: Ho, Sze Chun Winson
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.